Form 4: Decheng Capital Sells BYSI Shares Under 10b5-1 Plan

Decheng Capital, a 10% owner and director of BeyondSpring Inc., reported the sale of 4,110 ordinary shares in multiple transactions in mid-September 2025 under a pre-arranged 10b5-1 plan.

Summary

• Decheng Capital China Life Sciences USD Fund III, L.P., identified as a 10% owner and director of BeyondSpring Inc. (BYSI), reported the sale of ordinary shares.
• The transactions occurred on September 12, 2025, September 15, 2025, and September 16, 2025.
• A total of 4,110 ordinary shares were sold across these three dates.
• On September 12, 2025, 700 shares were sold at a weighted average price of $1.85 per share, with prices ranging from $1.83 to $1.87.
• On September 15, 2025, 2,570 shares were sold at a weighted average price of $1.84 per share, with prices ranging from $1.77 to $1.87.
• On September 16, 2025, 840 shares were sold at a weighted average price of $1.88 per share, with prices ranging from $1.86 to $1.90.
• Following these transactions, Decheng Capital China Life Sciences USD Fund III, L.P. beneficially owns 1,870,600 ordinary shares.
• Other related entities, Decheng Capital China Life Sciences USD Fund II, L.P. and Decheng Capital Global Healthcare Fund (Master), LP, beneficially own 1,617,409 and 891,734 ordinary shares, respectively.
• The reported sales were executed pursuant to a Rule 10b5-1(c) plan.

Sentiment

Score: 4

Explanation: The sentiment is moderately negative due to insider selling by a significant shareholder and director. While the sales are under a 10b5-1 plan, which reduces the immediate negative signal, any reduction in insider holdings can be viewed with caution by investors.

Positives

• The sales were executed under a pre-arranged Rule 10b5-1(c) plan, which suggests the transactions are systematic and not necessarily indicative of new negative information or a change in the insider's view of the company's prospects.

Negatives

• A significant shareholder and director, Decheng Capital, reduced its stake in BeyondSpring Inc. by selling 4,110 ordinary shares.
• Insider selling, even if pre-planned, can sometimes be perceived negatively by the market as it reduces the insider's direct financial alignment with the company's future stock performance.

Risks

• Potential negative market perception due to insider selling, which could put downward pressure on the stock price.
• Reduced alignment of a significant shareholder and director with the long-term interests of other shareholders.

Future Outlook

NA

Management Comments

• The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Industry Context

This filing reflects routine insider transaction reporting for a publicly traded company. While not directly tied to broader industry trends, insider selling can sometimes be a signal within the sector, though the 10b5-1 plan mitigates immediate concerns about opportunistic selling.

Related Party Transactions

• The sales of ordinary shares by Decheng Capital China Life Sciences USD Fund III, L.P. are considered related party transactions as Decheng Capital is a 10% owner and has a director (Dr. Xiangmin Cui) on the board of BeyondSpring Inc.

Stakeholder Impact

• Shareholders may perceive the insider selling as a negative signal, potentially leading to downward pressure on the stock price. However, the 10b5-1 plan mitigates the immediate concern of opportunistic selling.
• Company management might face questions regarding the long-term commitment of a significant investor, although the 10b5-1 plan provides a structured reason for the transactions.

Key Dates

Recommendation

While the insider selling by a 10% owner and director is generally a negative signal, the fact that these transactions were executed under a pre-arranged Rule 10b5-1 plan suggests they are systematic and not necessarily driven by new, adverse material information. Given this context, and without additional financial or operational updates from the company, a 'hold' recommendation is appropriate. Investors should monitor future filings and company performance for further insights rather than reacting solely to these pre-planned sales.

Keywords

BeyondSpring Inc., BYSI, Decheng Capital, Insider Selling, Form 4, Share Sale, Equity Transaction, 10b5-1 Plan, Director Transaction, 10% Owner